广州威溶特

Virotech Pharmaceutical is a clinical-stage biotechnology company based in Guangzhou, China, specializing in the development of next-generation oncolytic virus therapies. The company's core technology is based on the M1 virus, a naturally occurring alphavirus that selectively targets and kills Zinc finger CCCH-type antiviral protein 1 (ZAP)-deficient cancer cells while sparing healthy tissue. Virotech is advancing a diverse pipeline of M1-based candidates for various solid tumors, including hepatocellular carcinoma and colorectal cancer, as well as complications like malignant pleural effusion. Their approach combines direct viral oncolysis with the stimulation of systemic anti-tumor immune responses. The company has established a complete industrial chain encompassing R&D, clinical development, and GMP manufacturing for viral vectors.